Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Phase Ib/IIa randomized double-blind placebo-controlled dose-escalation study of IMC-003 in pulmonary arterial hypertension
CTR20261687Phase 2Active
- Sponsor
- ImmunoCare
- Start
- Jun 2026
- Countries
- 1
01
Overview
A Phase 2 trial of IMC-003 in pulmonary arterial hypertension (PAH), sponsored by ImmunoCare. Started Jun 2026; status: active.
02
Drugs
IMC-003
03
Conditions
pulmonary arterial hypertension (PAH)
Beyond the preview
Go deeper on CTR20261687.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on CTR20261687.